SGLT2 Inhibition in Heart Failure with a Preserved Ejection Fraction — A Win against a Formidable Foe

Mark Drazner comments on the findings of the EMPEROR-Preserved trial, which assessed the potential benefit of empagliflozin in patients with a preserved EF. He notes that the findings represent a major win against a medical condition that had previously proved formidable.